Spyre Therapeutics Director Henderson Offloads $2 Million in Equity Under Pre-Arranged Plan
Michael Thomas Henderson, a member of the board at Spyre Therapeutics Inc. (NASDAQ: SYRE), executed a transaction to sell 20,000 shares of the company's common equity on June 22, 2026. The disposition of these shares resulted in a gross transaction value of $2,000,000, with each share priced at $100. This activity follows a period of significant pr…